NYSE:DNALife Sciences
Ginkgo Bioworks (DNA): Assessing Valuation Following Major ARPA-H-Backed Phage Therapy Collaboration
Ginkgo Bioworks (NYSE:DNA) just unveiled a strategic partnership with the University of Illinois Urbana-Champaign's Institute for Genomic Biology, launching a five-year research effort funded by ARPA-H. This move could broaden Ginkgo's reach in phage therapy innovation.
See our latest analysis for Ginkgo Bioworks Holdings.
The recent rally in Ginkgo Bioworks’ total shareholder return, a strong 24% gain over the past year, stands out, especially as the share price has struggled in 2025. While...